ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4.
Autor: | Tianxing Zhou, Jing Liu, Yongjie Xie, Shuai Yuan, Yu Guo, Weiwei Bai, Kaili Zhao, Wenna Jiang, Hongwei Wang, Haotian Wang, Tiansuo Zhao, Chongbiao Huang, Song Gao, Xiuchao Wang, Shengyu Yang, Jihui Hao |
---|---|
Předmět: | |
Zdroj: | Gut; Feb2022, Vol. 71 Issue 2, p357-371, 63p |
Databáze: | Complementary Index |
Externí odkaz: |